Nisa Investment Advisors LLC Sells 367 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Nisa Investment Advisors LLC decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDPGet Rating) by 14.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,204 shares of the company’s stock after selling 367 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Medpace were worth $391,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of MEDP. Liberty Wealth Management LLC lifted its holdings in shares of Medpace by 67.1% in the third quarter. Liberty Wealth Management LLC now owns 137 shares of the company’s stock worth $28,000 after acquiring an additional 55 shares during the last quarter. USA Financial Portformulas Corp bought a new position in shares of Medpace in the third quarter worth about $62,000. Clearstead Advisors LLC lifted its holdings in shares of Medpace by 126.0% in the third quarter. Clearstead Advisors LLC now owns 339 shares of the company’s stock worth $64,000 after acquiring an additional 189 shares during the last quarter. Stephens Inc. AR bought a new position in shares of Medpace in the third quarter worth about $77,000. Finally, Marshall Wace LLP bought a new position in shares of Medpace in the first quarter worth about $99,000. 96.88% of the stock is owned by institutional investors and hedge funds.

A number of research analysts have recently commented on MEDP shares. StockNews.com started coverage on shares of Medpace in a report on Thursday, March 31st. They issued a “buy” rating for the company. Robert W. Baird upped their price objective on Medpace from $160.00 to $175.00 in a research note on Thursday, March 17th. Finally, Zacks Investment Research downgraded Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, February 19th.

Medpace stock opened at $150.62 on Friday. The business has a 50 day moving average of $154.84 and a 200-day moving average of $184.55. Medpace Holdings, Inc. has a 1 year low of $136.80 and a 1 year high of $231.00. The company has a market capitalization of $5.07 billion, a P/E ratio of 31.31 and a beta of 1.48.

Medpace (NASDAQ:MEDPGet Rating) last released its quarterly earnings data on Sunday, February 13th. The company reported $1.32 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.25 by $0.07. The company had revenue of $308.55 million during the quarter, compared to the consensus estimate of $309.03 million. Medpace had a return on equity of 20.55% and a net margin of 15.92%. The firm’s revenue was up 18.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.39 earnings per share. As a group, equities research analysts predict that Medpace Holdings, Inc. will post 5.57 EPS for the current fiscal year.

About Medpace (Get Rating)

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.

See Also

Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDPGet Rating).

Institutional Ownership by Quarter for Medpace (NASDAQ:MEDP)

Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.